- Home
- / Orchard Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Orchard Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$16.7
2024-02-02
Market Capitalization
$380.1 M
2024-02-02
Revenue
$22.7 M
FY, 2022
CreditSafe Score
?
Score changed on Oct 04, 2024
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 |
|---|---|---|---|---|---|
| Revenue | 2.1M | 2.5M | 2.6M | 1.7M | 22.7M |
| Cost of goods sold | 422.0K | 805.0K | 857.0K | 226.0K | 6.8M |
| Gross profit | 1.7M | 1.7M | 1.7M | 1.4M | 15.9M |
| Gross profit margin, % | 79.7% | 68.0% | 67.0% | 86.5% | 70.1% |
| General and administrative expense | 31.4M | 57.2M | 65.0M | 54.9M | 49.1M |
| Operating expense total | 236.7M | 174.6M | 158.7M | 141.9M | 143.0M |
| EBIT | (235.0M) | (172.9M) | (157.0M) | (140.4M) | (127.1M) |
| EBIT margin, % | -11321.3% | -6879.1% | -6049.2% | -8384.1% | -561.0% |
| Interest income | 7.4M | 3.2M | 412.0K | 1.5M | |
| Interest expense | 1.1M | 1.5M | 2.3M | 2.5M | 3.1M |
| Pre tax profit | (229.5M) | (165.7M) | (152.7M) | (143.8M) | (153.0M) |
| Income tax expense | 970.0K | (2.2M) | (731.0K) | 828.0K | (2.4M) |
| Net Income | (230.5M) | (163.4M) | (152.0M) | (144.6M) | (150.7M) |
| EPS | (1.2) |